UBX6 Antibody

What is UBXN6/UBXD1 and what cellular functions does it regulate?

UBXN6 (also known as UBXD1) is a UBX domain-containing protein that serves as an essential cofactor for valosin-containing protein p97, an ATP-driven segregase involved in diverse cellular activities . This protein is expressed across various tissues, with higher expression levels observed in skeletal muscle, heart, and kidney .

UBXN6 contributes to several crucial cellular processes:

• Assists in the disassembly of protein substrates tagged for degradation, contributing to protein quality control

• Regulates endoplasmic reticulum-associated degradation (ERAD) of misfolded proteins

• Acts as an activator of autophagy pathways

• Regulates inflammatory responses, particularly in the context of sepsis

• Positively regulates JAK-STAT1/2 signaling by stabilizing key components like TYK2

What types of UBXN6/UBXD1 antibodies are available for research applications?

Currently, several validated rabbit polyclonal antibodies targeting UBXN6/UBXD1 are available for research applications. These include:

Most of these antibodies target epitopes within the N-terminal region of UBXN6/UBXD1 protein and have been validated for applications including Western blotting, immunofluorescence, and immunohistochemistry .

What are the optimal conditions for detecting UBXN6/UBXD1 in Western blot applications?

For optimal Western blot detection of UBXN6/UBXD1, researchers should:

• Sample preparation: Use protein lysates from tissues with known expression (brain, kidney, heart) or cell lines such as HeLa or PC-3 cells

• Expected molecular weight: Look for a band at approximately 49-50 kDa

• Antibody dilution:

  • For Proteintech 14706-1-AP: Use at 1:1000-1:4000 dilution

  • For Abcam ab221167: Use at 1:500 dilution

• Blocking solution: 5% non-fat milk in TBST is typically effective

• Detection system: Both chemiluminescence and fluorescence-based systems work well

When troubleshooting, remember that UBXN6/UBXD1 is expressed at different levels across tissues, with skeletal muscle, heart, and kidney showing higher expression levels . Using positive control lysates from these tissues can help validate antibody performance.

How should UBXN6/UBXD1 immunofluorescence experiments be optimized?

For successful immunofluorescence detection of UBXN6/UBXD1:

• Fixation method: PFA fixation (typically 4%) followed by Triton X-100 permeabilization works effectively

• Antibody concentration:

  • For Abcam ab221167: Use at approximately 4 μg/ml

  • For Proteintech 14706-1-AP: Use at 1:200-1:800 dilution

• Cell types: HeLa cells show consistent positive staining and can serve as a reliable positive control

• Controls: Include negative controls (primary antibody omission) and compare to known cellular localization patterns

• Visualization: Confocal microscopy is recommended for detailed subcellular localization

Researchers should observe predominantly cytoplasmic localization with some enrichment in specialized compartments depending on the cell type being studied.

How can UBXN6/UBXD1 antibodies be used to investigate autophagy pathways?

Recent research has identified UBXN6 as an important activator of autophagy pathways . To investigate this role:

• Experimental design: Compare autophagy markers in UBXN6-sufficient versus UBXN6-deficient cells using techniques such as:

  • Immunoblotting for LC3-I to LC3-II conversion

  • Fluorescence microscopy for autophagic vesicle formation

  • Co-immunoprecipitation to detect UBXN6 interactions with autophagy machinery

• Methodology for co-localization studies:

  • Perform double immunofluorescence staining with UBXN6 antibody (1:200-1:800) and markers of autophagy (LC3, p62)

  • Use super-resolution microscopy for detailed co-localization analysis

• Functional assays:

  • Autophagy flux assays using bafilomycin A1 in UBXN6 knockdown cells

  • Lysosomal biogenesis assessment through transcription factor EB (TFEB) nuclear translocation

Research has shown that UBXN6-deficient macrophages exhibit impaired autophagy and endoplasmic reticulum-associated degradation pathways, accompanied by increased mitochondrial oxidative stress and exacerbated inflammation .

What approaches can be used to study UBXN6's role in inflammatory regulation using these antibodies?

To investigate UBXN6's role in inflammatory regulation:

• Experimental systems:

  • Human sepsis patient samples (UBXN6 is upregulated in sepsis)

  • Myeloid cell-specific UBXN6 knockout mouse models

  • THP-1 cell line with UBXN6 knockdown using siRNA transfection

• Analytical approaches:

  • Gene expression profiling of inflammatory cytokines

  • Western blot analysis of inflammatory signaling pathways

  • Immunofluorescence co-localization with inflammatory signaling components

• Key measurements:

  • UBXN6 expression levels correlate negatively with inflammatory gene profiles

  • UBXN6 expression correlates positively with FOXO3 (autophagy-driving transcription factor)

  • Assessment of metabolic shifts in UBXN6-deficient cells using metabolomics

Research has demonstrated that UBXN6-deficient macrophages exhibit immunometabolic remodeling, characterized by increased aerobic glycolysis and elevated levels of branched-chain amino acids, which amplifies mTOR pathway signaling .

What validation approaches should be used to confirm UBXN6/UBXD1 antibody specificity?

To ensure antibody specificity for UBXN6/UBXD1:

• Genetic approach:

  • Use UBXN6 knockout/knockdown cells as negative controls

  • Demonstrate loss of signal in Western blot, immunofluorescence, or immunohistochemistry

• Molecular validation:

  • Confirm expected molecular weight (49-50 kDa) in Western blot

  • Pre-absorption controls with immunizing peptide

  • Test antibody reactivity across multiple tissue/cell types with known expression patterns

• Orthogonal methods:

  • Verify protein expression using multiple antibodies targeting different epitopes

  • Correlate protein detection with mRNA expression data

  • Use tagged-UBXN6 overexpression systems as positive controls

The validation strategy should be tailored to the specific research application, with strongest validation coming from genetic approaches coupled with orthogonal methods.

How can UBXN6/UBXD1 siRNA transfection protocols be optimized for functional studies?

For effective UBXN6 knockdown in functional studies:

• Protocol for adherent cells:

  • Seed cells at 50-70% confluence

  • Mix 40 pmol of UBXN6-specific siRNA with transfection reagent (e.g., Lipofectamine 2000)

  • Prepare in serum-free medium, incubate for 15-20 minutes before adding to cells

  • Incubate for 48-72 hours before assessing knockdown efficiency

• Protocol for THP-1 cells (monocytic cell line):

  • Differentiate THP-1 cells with 10 ng/ml PMA for 3 days

  • Replace medium with complete RPMI

  • Transfect with UBXN6-specific siRNA (three 27-mer siRNAs recommended)

  • Incubate for 48 hours before experimentation

• Verification of knockdown:

  • Western blot using UBXN6 antibody at recommended dilutions

  • qRT-PCR for UBXN6 mRNA levels

  • Functional readouts of pathways regulated by UBXN6

Following knockdown, researchers can assess effects on various pathways, including JAK-STAT signaling, ISG expression, and viral replication responses .

How can UBXN6/UBXD1 antibodies be used to study its role in JAK-STAT signaling and antiviral responses?

Recent research has identified UBXN6 as a positive regulator of JAK-STAT1/2 signaling . To investigate this:

• Experimental approaches:

  • Co-immunoprecipitation to detect UBXN6 interaction with TYK2

  • Reporter assays using ISRE-Luc and Act-Renilla plasmids in UBXN6-deficient cells

  • Western blotting to assess phosphorylation status of STAT1/2 following IFN stimulation

• Key protocols:

  • Transfect cells with UBXN6-specific siRNA followed by luciferase reporter plasmids

  • Quantify luciferase 16 hours after the second transfection

  • Measure ISG expression by qRT-PCR or Western blot in UBXN6-deficient cells

• Findings to validate:

  • UBXN6 interacts with TYK2 and inhibits IFN-β-induced degradation of both TYK2 and type I IFN receptor

  • UBXN6-deficient cells show reduced ISG expression

  • Viral replication increases in UBXN6-deficient cell lines

This research approach has demonstrated that UBXN6 maintains normal JAK-STAT1/2 signaling by stabilizing key signaling components during viral infection .

What are the most effective experimental designs to study UBXN6's role in protein quality control and ERAD pathways?

To investigate UBXN6's function in protein quality control and ERAD:

• Experimental systems:

  • UBXN6 knockout/knockdown cell lines

  • Cells expressing ERAD substrates (e.g., mutant CFTR, TCRα)

  • Co-expression studies with VCP/p97 and UBXN6

• Analytical approaches:

  • Pulse-chase assays to measure degradation kinetics of ERAD substrates

  • Co-immunoprecipitation to identify UBXN6 interactions with ERAD machinery

  • Subcellular fractionation combined with Western blotting to track substrate localization

• Advanced techniques:

  • Proximity labeling (BioID or APEX) with UBXN6 to identify interacting partners

  • Live-cell imaging to track dynamics of UBXN6 during ER stress

  • Proteasome activity assays in UBXN6-deficient versus control cells

Research has demonstrated that UBXN6 may negatively regulate the ATPase activity of VCP/p97, an ATP-driven segregase that controls a wide variety of cellular processes . It also plays a role in the transport of CAV1 to lysosomes for degradation and in the endoplasmic reticulum-associated degradation of misfolded proteins .